The Role of Iodine-124-Positron Emission Tomography Imaging in the Management of Patients with Thyroid Cancer

PET Clinics

Volumn 2, Issue 3, 2007, Pages 313-320

  Grewal, Ravinder K ^a   Lubberink, Mark ^b   Pentlow, Keith S ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dosimetry; Iodine 124; Thyroid cancer

Indexed keywords

3 IODOBENZOIC ACID; IODINE 123; IODINE 124; IODINE 131;

AGED; CANCER CELL; CASE REPORT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HUMAN; IMAGE QUALITY; MALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THYROID CANCER;

EID: 64749093892     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.05.001     Document Type: Review

References (28)

1. Mankoff D.A. A definition of molecular imaging. J Nucl Med 48 (2007) 18N 21N
2. Erdi Y.E., Macapinlac H., Larson S.M., et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging 2 (1999) 41-46
3. Phillips A.F., Haybittle J.L., and Newbery G.R. Use of Iodine-124 for the treatment of carcinoma of the thyroid. Acta Unio Int Contra Cancrum 16 (1960) 1434-1438
4. Pentlow K.S., Graham M.C., Lambrecht R.M., et al. Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18 (1991) 357-366
5. Pentlow K.S., Graham M.C., Lambrecht R.M., et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 37 (1996) 1557-1562
6. Rault E., Vandenberghe S., Van Holen R., et al. Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131). Cancer Biother Radiopharm 22 (2007) 423-430
7. Glaser M., Luthra S.K., and Brady F. Applications of positron-emitting halogens in PET oncology (Review). Int J Oncol 22 (2003) 253-267
8. Herzog H., Tellman L., Qaim S.M., et al. PET quantitation and imaging of the non-pure positron-emitting iodine isotope 124I. Appl Radiat Isot 56 (2002) 673-679
9. Pentlow K.S., Finn R.D., Larson S.M., et al. Quantitative imaging of Yttrium-86 with PET. The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging 3 (2000) 85-90
10. Lubberink M., Schneider H., Bergstrom M., et al. Quantitative imaging and correction for cascade gamma radiation of 76Br with 2D and 3D PET. Phys Med Biol 47 (2002) 3519-3534
11. Beattie B.J., Finn R.D., Rowland D.J., et al. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys 30 (2003) 2410-2423
12. Kolthammer J., Salem N., Fiedler K., et al. Downscatter contamination from high-energy photons of I-124 in 2D and 3D PET. IEEE 2004. Nuclear Science Symposium Conference record (2004) 3629-3633
13. Lubberink M., van Schie A., de Jong H.W., et al. Acquisition settings for PET of 124-I administered simultaneously with therapeutic amounts of 131I. J Nucl Med 47 (2006) 1375-1381
14. Freudenberg L.S., Antoch G., Jentzen W., et al. Value of I-124-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14 (2004) 2092-2098
15. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 (2000) 1369-1379
16. Freudenberg L.S., Antoch G., Gorges R., et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 13 (2003) L19-L23
17. Larson S.M., and Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 37 (2002) 169-174
18. Eschmann S.M., Reischl G., Bilger K., et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29 (2002) 760-767
19. Dorn R., Kopp J., Vogt H., et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med 44 (2003) 451-456
20. Sgouros G., Kolbert K.S., Sheikh A., et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 (2004) 1366-1372
21. Kolbert K.S., and Sgouros G. Display and manipulation of SPECT and CT studies for radiolabeled antibody therapy. [Abstract]. Cancer Biother Radiopharm 302 (1998)
22. Kolbert K.S., Pentlow K.S., Pearson J.R., et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with I-131 by use of I-124 PET and 3-dimensional internal dosimetry software. J Nucl Med 48 (2007) 143-149
23. Freudenberg L.S., Jentzen W., Gorges R., et al. I-124-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact. Nuklearmedizin 46 (2007) 121-128
24. Freudenberg L.S., Jentzen W., Marlowe R.J., et al. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer. Exp Clin Endocrinol Diabetes 115 (2007) 690-693
25. Van Nostrand D. New approaches in nuclear medicine for thyroid cancer (2006), Humana Press, Totowa (NJ)
26. Dingli D., Kemp B.J., O'Connor M.K., et al. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol 8 (2006) 16-23
27. Keen H.G., Dekker B.A., Disley L., et al. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl Med Biol 32 (2005) 395-402
28. Dekker B., Keen H., Lyons S., et al. MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol 32 (2005) 241-252